Based on the findings of this research, we recommend that a system be considered to ensure that all patients with Cr antigenaemia are offered an LP to exclude CCM, and that the cut-off point for assessing Cr antigenaemia be increased to a CD4 count of 150 cells/mm3. This evidence concerns the gene CD4 and cerebral cavernous malformation.